By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CLC Bio will develop a bioinformatics platform for Aarhus University Hospital to support an interdisciplinary genomics study that seeks to develop new tools for predicting prostate cancer risk and aggressiveness.

The Danish company said today that it will develop a platform for analyzing microarray and next-generation sequencing data for the multi-partner study, which is funded with $4 million by the Danish Council for Strategic Research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease. 

Jun
23
Sponsored by
PerkinElmer

This webinar will demonstrate how automated liquid handling workstations can reduce bottlenecks in library preparation for next-generation sequencing, enabling scientific advances in genomics research that were not possible five years ago.